# PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

> **NCT01566773** · PHASE2 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 140 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** PT001 MDI
- **DRUG:** Tiotropium Bromide
- **DRUG:** PT001 Placebo MDI

## Key facts

- **NCT ID:** NCT01566773
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2017-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01566773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01566773, "PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01566773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*